Skip to main content
. 2016 Jul 31;11(3):91–104. doi: 10.1177/1753944716652787

Figure 5.

Figure 5.

Stroke and systemic embolism in patients with and without previous stroke and treated with warfarin versus apixaban. With prior CVA: 2.46% per year on apixaban versus 3.24% per year on warfarin [hazard ratio (HR) for apixaban 0.76]; without prior CVA: 1.01% per year on apixaban versus 1.32 per year on warfarin (HR for apixaban 0.82); p for interaction = 0.71 [Easton et al. 2012].

TIA, transient ischemic attack.